Hexavac

Hexavac was a hexavalent combination vaccine developed by Aventis Pasteur MSD for the primary and booster immunization of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). It contained diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid and filamentous haemagglutinin), recombinant hepatitis B surface antigen, inactivated poliovirus (types 1, 2, and 3), and Hib capsular polysaccharide conjugated to tetanus protein. Authorized in the European Union in 2000, the vaccine was suspended in 2005 and subsequently withdrawn from the market due to concerns regarding the long-term immunogenicity of its hepatitis B component, specifically a potential decrease in protection over time compared to other vaccines.